<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33374253</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>12</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>12</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">2073-4409</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>10</Volume>
            <Issue>1</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Dec</Month>
              <Day>24</Day>
            </PubDate>
          </JournalIssue>
          <Title>Cells</Title>
          <ISOAbbreviation>Cells</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Myeloid Cells in Glioblastoma Microenvironment.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">18</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/cells10010018</ELocationID>
        <Abstract>
          <AbstractText>Glioblastoma (GBM) is the most aggressive, malignant primary brain tumor in adults. GBM is notoriously resistant to immunotherapy mainly due to its unique immune microenvironment. High dimensional data analysis reveals the extensive heterogeneity of immune components making up the GBM microenvironment. Myeloid cells are the most predominant contributors to the GBM microenvironment; these cells are critical regulators of immune and therapeutic responses to GBM. Here, we will review the most recent advances on the characteristics and functions of different populations of myeloid cells in GBM, including bone marrow-derived macrophages, microglia, myeloid-derived suppressor cells, dendritic cells, and neutrophils. Epigenetic, metabolic, and phenotypic peculiarities of microglia and bone marrow-derived macrophages will also be assessed. The final goal of this review will be to provide new insights into novel therapeutic approaches for specific targeting of myeloid cells to improve the efficacy of current treatments in GBM patients.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>De Leo</LastName>
            <ForeName>Alessandra</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0003-3630-5765</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9416, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ugolini</LastName>
            <ForeName>Alessio</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-5970-9693</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9416, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Experimental Medicine, Sapienza University of Rome, 00185 Rome, Italy.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Veglia</LastName>
            <ForeName>Filippo</ForeName>
            <Initials>F</Initials>
            <Identifier Source="ORCID">0000-0001-6710-1584</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Immuno-Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612-9416, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>24</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Cells</MedlineTA>
        <NlmUniqueID>101600052</NlmUniqueID>
        <ISSNLinking>2073-4409</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D001932" MajorTopicYN="Y">Brain Neoplasms</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005909" MajorTopicYN="Y">Glioblastoma</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007167" MajorTopicYN="N">Immunotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017628" MajorTopicYN="Y">Microglia</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D022423" MajorTopicYN="Y">Myeloid Cells</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D059016" MajorTopicYN="Y">Tumor Microenvironment</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">brain cancers</Keyword>
        <Keyword MajorTopicYN="Y">dendritic cells</Keyword>
        <Keyword MajorTopicYN="Y">glioblastoma</Keyword>
        <Keyword MajorTopicYN="Y">glioma</Keyword>
        <Keyword MajorTopicYN="Y">microglia</Keyword>
        <Keyword MajorTopicYN="Y">myeloid cells</Keyword>
        <Keyword MajorTopicYN="Y">myeloid-derived suppressor cells</Keyword>
        <Keyword MajorTopicYN="Y">neutrophils</Keyword>
        <Keyword MajorTopicYN="Y">tumor-associated macrophages</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>30</Day>
          <Hour>1</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>12</Month>
          <Day>31</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>13</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33374253</ArticleId>
        <ArticleId IdType="pmc">PMC7824606</ArticleId>
        <ArticleId IdType="doi">10.3390/cells10010018</ArticleId>
        <ArticleId IdType="pii">cells10010018</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Brat D.J., Verhaak R.G.W., Aldape K.D., Yung W.K.A., Salama S.R., Cooper L.D.A., Rheinbay E., Miller C.R., Vitucci M., Morozova O., et al.  Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. N. Engl. J. Med. 2015;372:2481–2498. doi: 10.1056/NEJMoa1402121.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1402121</ArticleId>
            <ArticleId IdType="pmc">PMC4530011</ArticleId>
            <ArticleId IdType="pubmed">26061751</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verhaak R.G., Hoadley K.A., Purdom E., Wang V., Qi Y., Wilkerson M.D., Miller C.R., Ding L., Golub T., Mesirov J.P., et al.  Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110. doi: 10.1016/j.ccr.2009.12.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2009.12.020</ArticleId>
            <ArticleId IdType="pmc">PMC2818769</ArticleId>
            <ArticleId IdType="pubmed">20129251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Omuro A., DeAngelis L.M. Glioblastoma and other malignant gliomas: A clinical review. JAMA. 2013;310:1842–1850. doi: 10.1001/jama.2013.280319.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2013.280319</ArticleId>
            <ArticleId IdType="pubmed">24193082</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stupp R., Taillibert S., Kanner A., Read W., Steinberg D.M., Lhermitte B., Toms S., Idbaih A., Ahluwalia M.S., Fink K., et al.  Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma. JAMA. 2017;318:2306–2316. doi: 10.1001/jama.2017.18718.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2017.18718</ArticleId>
            <ArticleId IdType="pmc">PMC5820703</ArticleId>
            <ArticleId IdType="pubmed">29260225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Antunes A.R.P., Scheyltjens I., Duerinck J., Neyns B., Movahedi K., Van Ginderachter J.A. Understanding the glioblastoma immune microenvironment as basis for the development of new immunotherapeutic strategies. eLife. 2020;9 doi: 10.7554/elife.52176.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/elife.52176</ArticleId>
            <ArticleId IdType="pmc">PMC7000215</ArticleId>
            <ArticleId IdType="pubmed">32014107</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z., Feng X., Herting C.J., Garcia V.A., Nie K., Pong W.W., Rasmussen R., Dwivedi B., Seby S., Wolf S.A., et al.  Cellular and Molecular Identity of Tumor-Associated Macrophages in Glioblastoma. Cancer Res. 2017;77:2266–2278. doi: 10.1158/0008-5472.CAN-16-2310.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-16-2310</ArticleId>
            <ArticleId IdType="pmc">PMC5741820</ArticleId>
            <ArticleId IdType="pubmed">28235764</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson J.H., Gunn M.D., Fecci P.E., Ashley D.M. Brain immunology and immunotherapy in brain tumours. Nat. Rev. Cancer. 2020;20:12–25. doi: 10.1038/s41568-019-0224-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41568-019-0224-7</ArticleId>
            <ArticleId IdType="pmc">PMC7327710</ArticleId>
            <ArticleId IdType="pubmed">31806885</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tomaszewski W., Sanchez-Perez L., Gajewski T.F., Sampson J.H. Brain Tumor Microenvironment and Host State: Implications for Immunotherapy. Clin. Cancer Res. 2019;25:4202–4210. doi: 10.1158/1078-0432.CCR-18-1627.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-18-1627</ArticleId>
            <ArticleId IdType="pmc">PMC6635001</ArticleId>
            <ArticleId IdType="pubmed">30804019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ransohoff R.M., Engelhardt B. The anatomical and cellular basis of immune surveillance in the central nervous system. Nat. Rev. Immunol. 2012;12:623–635. doi: 10.1038/nri3265.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3265</ArticleId>
            <ArticleId IdType="pubmed">22903150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gentles A.J., Newman A.M., Liu C.L., Bratman S.V., Feng W., Kim D., Nair V.S., Xu Y., Khuong A., Hoang C.D., et al.  The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 2015;21:938–945. doi: 10.1038/nm.3909.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3909</ArticleId>
            <ArticleId IdType="pmc">PMC4852857</ArticleId>
            <ArticleId IdType="pubmed">26193342</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Quail D.F., Bowman R.L., Akkari L., Quick M.L., Schuhmacher A.J., Huse J.T., Holland E.C., Sutton J.C., Joyce J.A. The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas. Science. 2016;352:aad3018. doi: 10.1126/science.aad3018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aad3018</ArticleId>
            <ArticleId IdType="pmc">PMC5450629</ArticleId>
            <ArticleId IdType="pubmed">27199435</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Klemm F., Maas R.R., Bowman R.L., Kornete M., Soukup K., Nassiri S., Brouland J.-P., Iacobuzio-Donahue C.A., Brennan C., Tabar V., et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells. Cell. 2020;181:1643–1660.e17. doi: 10.1016/j.cell.2020.05.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.05.007</ArticleId>
            <ArticleId IdType="pubmed">32470396</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Friebel E., Kapolou K., Unger S., Núñez N.G., Utz S., Rushing E.J., Regli L., Weller M., Greter M., Tugues S., et al.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes. Cell. 2020;181:1626–1642.e20. doi: 10.1016/j.cell.2020.04.055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2020.04.055</ArticleId>
            <ArticleId IdType="pubmed">32470397</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang Y., Kim B.Y., Chan C.K., Hahn S.M., Weissman I.L., Jiang W. Improving immune–vascular crosstalk for cancer immunotherapy. Nat. Rev. Immunol. 2018;18:195–203. doi: 10.1038/nri.2017.145.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri.2017.145</ArticleId>
            <ArticleId IdType="pmc">PMC5922422</ArticleId>
            <ArticleId IdType="pubmed">29332937</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cristescu R., Mogg R., Ayers M., Albright A., Murphy E., Yearley J., Sher X., Liu X.Q., Lu H., Nebozhyn M., et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy. Science. 2018;362:eaar3593. doi: 10.1126/science.aar3593.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.aar3593</ArticleId>
            <ArticleId IdType="pmc">PMC6718162</ArticleId>
            <ArticleId IdType="pubmed">30309915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chongsathidkiet P., Jackson C., Koyama S., Loebel F., Cui X., Farber S.H., Woroniecka K., Elsamadicy A.A., DeChant C.A., Kemeny H.R., et al.  Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat. Med. 2018;24:1459–1468. doi: 10.1038/s41591-018-0135-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-018-0135-2</ArticleId>
            <ArticleId IdType="pmc">PMC6129206</ArticleId>
            <ArticleId IdType="pubmed">30104766</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Martinez-Lage M., Lynch T.M., Bi Y., Cocito C., Way G.P., Pal S., Haller J., Yan R.E., Ziober A., Nguyen A., et al.  Immune landscapes associated with different glioblastoma molecular subtypes. Acta Neuropathol. Commun. 2019;7:1–12. doi: 10.1186/s40478-019-0803-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40478-019-0803-6</ArticleId>
            <ArticleId IdType="pmc">PMC6902522</ArticleId>
            <ArticleId IdType="pubmed">31815646</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amankulor N.M., Kim Y., Arora S., Kargl J., Szulzewsky F., Hanke M., Margineantu D.H., Rao A., Bolouri H., Delrow J., et al.  Mutant IDH1 regulates the tumor-associated immune system in gliomas. Genes Dev. 2017;31:774–786. doi: 10.1101/gad.294991.116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gad.294991.116</ArticleId>
            <ArticleId IdType="pmc">PMC5435890</ArticleId>
            <ArticleId IdType="pubmed">28465358</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q.-W., Liu L., Gong C.-Y., Shi H.-S., Zeng Y.-H., Wang X.-Z., Zhao Y.-W., Wei Y.-Q. Prognostic Significance of Tumor-Associated Macrophages in Solid Tumor: A Meta-Analysis of the Literature. PLoS ONE. 2012;7:e50946.  doi: 10.1371/journal.pone.0050946.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0050946</ArticleId>
            <ArticleId IdType="pmc">PMC3532403</ArticleId>
            <ArticleId IdType="pubmed">23284651</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chanmee T., Ontong P., Konno K., Itano N. Tumor-associated macrophages as major players in the tumor microenvironment. Cancers. 2014;6:1670–1690. doi: 10.3390/cancers6031670.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers6031670</ArticleId>
            <ArticleId IdType="pmc">PMC4190561</ArticleId>
            <ArticleId IdType="pubmed">25125485</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur. Respir. J. 2009;33:118–126. doi: 10.1183/09031936.00065708.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1183/09031936.00065708</ArticleId>
            <ArticleId IdType="pubmed">19118225</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma J., Liu L., Che G.-W., Yu N., Dai F., You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer. 2010;10:112.  doi: 10.1186/1471-2407-10-112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-112</ArticleId>
            <ArticleId IdType="pmc">PMC2851690</ArticleId>
            <ArticleId IdType="pubmed">20338029</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Tumour necrosis factor-alpha expression in tumour islets confers a survival advantage in non-small cell lung cancer. BMC Cancer. 2010;10:323.  doi: 10.1186/1471-2407-10-323.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1471-2407-10-323</ArticleId>
            <ArticleId IdType="pmc">PMC2909205</ArticleId>
            <ArticleId IdType="pubmed">20573209</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye X.-Z., Xu S.-L., Xin Y.-H., Yu S.-C., Ping Y.-F., Chen L., Xiao H.-L., Wang B., Yi L., Wang Q.-L., et al.  Tumor-Associated Microglia/Macrophages Enhance the Invasion of Glioma Stem-like Cells via TGF-β1 Signaling Pathway. J. Immunol. 2012;189:444–453. doi: 10.4049/jimmunol.1103248.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.1103248</ArticleId>
            <ArticleId IdType="pubmed">22664874</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Markovic D.S., Glass R., Synowitz M., Rooijen N., Kettenmann H. Microglia stimulate the invasiveness of glioma cells by increasing the activity of metalloprotease-2. J. Neuropathol. Exp. Neurol. 2005;64:754–762. doi: 10.1097/01.jnen.0000178445.33972.a9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/01.jnen.0000178445.33972.a9</ArticleId>
            <ArticleId IdType="pubmed">16141784</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen X., Zhang L., Zhang I.Y., Liang J., Wang H., Ouyang M., Wu S., Da Fonseca A.C.C., Weng L., Yamamoto Y., et al.  RAGE Expression in Tumor-Associated Macrophages Promotes Angiogenesis in Glioma. Cancer Res. 2014;74:7285–7297. doi: 10.1158/0008-5472.CAN-14-1240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-14-1240</ArticleId>
            <ArticleId IdType="pmc">PMC4268204</ArticleId>
            <ArticleId IdType="pubmed">25326491</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lu-Emerson C., Snuderl M., Kirkpatrick N.D., Goveia J., Davidson C., Huang Y., Riedemann L., Taylor J., Ivy P., Duda D.G., et al.  Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro-Oncology. 2013;15:1079–1087. doi: 10.1093/neuonc/not082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/not082</ArticleId>
            <ArticleId IdType="pmc">PMC3714160</ArticleId>
            <ArticleId IdType="pubmed">23828240</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hussain S.F., Yang D., Suki D., Aldape K., Grimm E., Heimberger A.B. The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses1. Neuro-Oncology. 2006;8:261–279. doi: 10.1215/15228517-2006-008.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1215/15228517-2006-008</ArticleId>
            <ArticleId IdType="pmc">PMC1871955</ArticleId>
            <ArticleId IdType="pubmed">16775224</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu H., Leiss L., Yang N., Rygh C.B., Mitra S.S., Cheshier S.H., Weissman I.L., Huang B., Miletic H., Bjerkvig R., et al.  Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. Oncotarget. 2017;8:12145–12157. doi: 10.18632/oncotarget.14553.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.14553</ArticleId>
            <ArticleId IdType="pmc">PMC5355332</ArticleId>
            <ArticleId IdType="pubmed">28076333</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tabatabai G., Frank B., Mohle R., Weller M., Wick W. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain. 2006;129:2426–2435. doi: 10.1093/brain/awl173.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awl173</ArticleId>
            <ArticleId IdType="pubmed">16835250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kioi M., Vogel H., Schultz G., Hoffman R.M., Harsh G.R., Brown J.M. Inhibition of vasculogenesis, but not angiogenesis, prevents the recurrence of glioblastoma after irradiation in mice. J. Clin. Investig. 2010;120:694–705. doi: 10.1172/JCI40283.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI40283</ArticleId>
            <ArticleId IdType="pmc">PMC2827954</ArticleId>
            <ArticleId IdType="pubmed">20179352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walters M.J., Ebsworth K., Berahovich R.D., Penfold M.E.T., Liu S.-C., Al Omran R., Kioi M., Chernikova S.B., Tseng D., Mulkearns-Hubert E.E., et al.  Inhibition of CXCR7 extends survival following irradiation of brain tumours in mice and rats. Br. J. Cancer. 2014;110:1179–1188. doi: 10.1038/bjc.2013.830.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/bjc.2013.830</ArticleId>
            <ArticleId IdType="pmc">PMC3950859</ArticleId>
            <ArticleId IdType="pubmed">24423923</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akkari L., Bowman R.L., Tessier J., Klemm F., Handgraaf S.M., De Groot M., Quail D.F., Tillard L., Gadiot J., Huse J.T., et al.  Dynamic changes in glioma macrophage populations after radiotherapy reveal CSF-1R inhibition as a strategy to overcome resistance. Sci. Transl. Med. 2020;12:eaaw7843. doi: 10.1126/scitranslmed.aaw7843.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aaw7843</ArticleId>
            <ArticleId IdType="pubmed">32669424</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L., Pollard J.W. Tumor-associated macrophages. Curr. Biol. 2020;30:R246–R248. doi: 10.1016/j.cub.2020.01.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cub.2020.01.031</ArticleId>
            <ArticleId IdType="pubmed">32208142</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Franklin R.A., Liao W., Sarkar A., Kim M.V., Bivona M.R., Liu K., Pamer E.G., Li M. The cellular and molecular origin of tumor-associated macrophages. Science. 2014;344:921–925. doi: 10.1126/science.1252510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1252510</ArticleId>
            <ArticleId IdType="pmc">PMC4204732</ArticleId>
            <ArticleId IdType="pubmed">24812208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ginhoux F., Guilliams M. Tissue-Resident Macrophage Ontogeny and Homeostasis. Immunity. 2016;44:439–449. doi: 10.1016/j.immuni.2016.02.024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.02.024</ArticleId>
            <ArticleId IdType="pubmed">26982352</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bennett M.L., Bennett F.C., Liddelow S.A., Ajami B., Zamanian J.L., Fernhoff N.B., Mulinyawe S.B., Bohlen C.J., Adil A., Tucker A., et al.  New tools for studying microglia in the mouse and human CNS. Proc. Natl. Acad. Sci. USA. 2016;113:E1738–E1746. doi: 10.1073/pnas.1525528113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1525528113</ArticleId>
            <ArticleId IdType="pmc">PMC4812770</ArticleId>
            <ArticleId IdType="pubmed">26884166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korzhevskii D.E., Kirik O.V. Brain Microglia and Microglial Markers. Neurosci. Behav. Physiol. 2016;46:284–290. doi: 10.1007/s11055-016-0231-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11055-016-0231-z</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sousa C., Biber K., Michelucci A. Cellular and Molecular Characterization of Microglia: A Unique Immune Cell Population. Front. Immunol. 2017;8:198. doi: 10.3389/fimmu.2017.00198.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00198</ArticleId>
            <ArticleId IdType="pmc">PMC5332364</ArticleId>
            <ArticleId IdType="pubmed">28303137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ford A.L., Goodsall A.L., Hickey W.F., Sedgwick J.D. Normal adult ramified microglia separated from other central nervous system macrophages by flow cytometric sorting. Phenotypic differences defined and direct ex vivo antigen presentation to myelin basic protein-reactive CD4+ T cells compared. J. Immunol. 1995;154:4309–4321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">7722289</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller A., Brandenburg S., Turkowski K., Müller S., Vajkoczy P. Resident microglia, and not peripheral macrophages, are the main source of brain tumor mononuclear cells. Int. J. Cancer. 2015;137:278–288. doi: 10.1002/ijc.29379.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.29379</ArticleId>
            <ArticleId IdType="pubmed">25477239</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Satoh J.-I., Kino Y., Asahina N., Takitani M., Miyoshi J., Ishida T., Saito Y. TMEM119 marks a subset of microglia in the human brain. Neuropathol. 2015;36:39–49. doi: 10.1111/neup.12235.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/neup.12235</ArticleId>
            <ArticleId IdType="pubmed">26250788</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bowman R.L., Klemm F., Akkari L., Pyonteck S.M., Sevenich L., Quail D.F., Dhara S., Simpson K., Gardner E.E., Iacobuzio-Donahue C.A., et al.  Macrophage Ontogeny Underlies Differences in Tumor-Specific Education in Brain Malignancies. Cell Rep. 2016;17:2445–2459. doi: 10.1016/j.celrep.2016.10.052.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2016.10.052</ArticleId>
            <ArticleId IdType="pmc">PMC5450644</ArticleId>
            <ArticleId IdType="pubmed">27840052</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pinton L., Masetto E., Vettore M., Solito S., Magri S., D’Andolfi M., Del Bianco P., Lollo G., Benoit J.-P., Okada H., et al.  The immune suppressive microenvironment of human gliomas depends on the accumulation of bone marrow-derived macrophages in the center of the lesion. J. Immunother. Cancer. 2019;7:58. doi: 10.1186/s40425-019-0536-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40425-019-0536-x</ArticleId>
            <ArticleId IdType="pmc">PMC6391795</ArticleId>
            <ArticleId IdType="pubmed">30813960</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Müller S., Kohanbash G., Liu S.J., Alvarado B., Carrera D., Bhaduri A., Watchmaker P.B., Yagnik G., Di Lullo E., Malatesta M., et al.  Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. Genome Biol. 2017;18:1–14. doi: 10.1186/s13059-017-1362-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-017-1362-4</ArticleId>
            <ArticleId IdType="pmc">PMC5738907</ArticleId>
            <ArticleId IdType="pubmed">29262845</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Poon C.C., Gordon P.M.K., Liu K., Yang R., Sarkar S., Mirzaei R., Ahmad S.T., Hughes M.L., Yong V.W., Kelly J.J. Differential microglia and macrophage profiles in human IDH-mutant and -wild type glioblastoma. Oncotarget. 2019;10:3129–3143. doi: 10.18632/oncotarget.26863.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.26863</ArticleId>
            <ArticleId IdType="pmc">PMC6517100</ArticleId>
            <ArticleId IdType="pubmed">31139325</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hambardzumyan D., Gutmann D.H., Kettenmann H. The role of microglia and macrophages in glioma maintenance and progression. Nat. Neurosci. 2016;19:20–27. doi: 10.1038/nn.4185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nn.4185</ArticleId>
            <ArticleId IdType="pmc">PMC4876023</ArticleId>
            <ArticleId IdType="pubmed">26713745</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Platten M., Kretz A., Naumann U., Aulwurm S., Egashira K., Isenmann S., Weller M. Monocyte chemoattractant protein-1 increases microglial infiltration and aggressiveness of gliomas. Ann. Neurol. 2003;54:388–392. doi: 10.1002/ana.10679.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.10679</ArticleId>
            <ArticleId IdType="pubmed">12953273</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang S.C., Hong J.H., Hsueh C., Chiang C.S. Tumor-secreted SDF-1 promotes glioma invasiveness and TAM tropism toward hypoxia in a murine astrocytoma model. Lab. Investig. 2012;92:151–162. doi: 10.1038/labinvest.2011.128.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/labinvest.2011.128</ArticleId>
            <ArticleId IdType="pubmed">21894147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Komohara Y., Ohnishi K., Kuratsu J., Takeya M. Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas. J. Pathol. 2008;216:15–24. doi: 10.1002/path.2370.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/path.2370</ArticleId>
            <ArticleId IdType="pubmed">18553315</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei J., Marisetty A., Schrand B., Gabrusiewicz K., Hashimoto Y., Ott M., Grami Z., Kong L.-Y., Ling X., Caruso H.G., et al.  Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J. Clin. Investig. 2018;129:137–149. doi: 10.1172/JCI121266.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI121266</ArticleId>
            <ArticleId IdType="pmc">PMC6307970</ArticleId>
            <ArticleId IdType="pubmed">30307407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahimi H., Minasi S., Ugolini A., Trevisi G., Napoletano C., Zizzari I.G., Gessi M., Giangaspero F., Mangiola A., Nuti M., et al.  Immunohistochemical Characterization of Immune Infiltrate in Tumor Microenvironment of Glioblastoma. J. Pers. Med. 2020;10:112.  doi: 10.3390/jpm10030112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/jpm10030112</ArticleId>
            <ArticleId IdType="pmc">PMC7564919</ArticleId>
            <ArticleId IdType="pubmed">32899203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Szulzewsky F., Pelz A., Feng X., Synowitz M., Markovic D., Langmann T., Holtman I.R., Wang X., Eggen B.J.L., Boddeke H.W.G.M., et al.  Glioma-Associated Microglia/Macrophages Display an Expression Profile Different from M1 and M2 Polarization and Highly Express Gpnmb and Spp1. PLoS ONE. 2015;10:e0116644.  doi: 10.1371/journal.pone.0116644.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0116644</ArticleId>
            <ArticleId IdType="pmc">PMC4320099</ArticleId>
            <ArticleId IdType="pubmed">25658639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sa J.K., Chang N., Lee H.W., Cho H.J., Ceccarelli M., Cerulo L., Yin J., Kim S.S., Caruso F.P., Lee M., et al.  Transcriptional regulatory networks of tumor-associated macrophages that drive malignancy in mesenchymal glioblastoma. Genome Biol. 2020;21:1–17. doi: 10.1186/s13059-020-02140-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13059-020-02140-x</ArticleId>
            <ArticleId IdType="pmc">PMC7448990</ArticleId>
            <ArticleId IdType="pubmed">32847614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maleszewska M., Steranka A., Smiech M., Kaza B., Pilanc P., Dabrowski M., Kaminska B. Sequential changes in histone modifications shape transcriptional responses underlying microglia polarization by glioma. Glia. 2021;69:109–123. doi: 10.1002/glia.23887.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/glia.23887</ArticleId>
            <ArticleId IdType="pubmed">32710676</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bader J.E., Voss K., Rathmell J.C. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy. Mol. Cell. 2020;78:1019–1033. doi: 10.1016/j.molcel.2020.05.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2020.05.034</ArticleId>
            <ArticleId IdType="pmc">PMC7339967</ArticleId>
            <ArticleId IdType="pubmed">32559423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gosselin D., Link V.M., Romanoski C.E., Fonseca G.J., Eichenfield D.Z., Spann N.J., Stender J.D., Chun H.B., Garner H., Geissmann F., et al.  Environment Drives Selection and Function of Enhancers Controlling Tissue-Specific Macrophage Identities. Cell. 2014;159:1327–1340. doi: 10.1016/j.cell.2014.11.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.11.023</ArticleId>
            <ArticleId IdType="pmc">PMC4364385</ArticleId>
            <ArticleId IdType="pubmed">25480297</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rodríguez-Prados J.-C., Través P.G., Cuenca J., Rico D., Aragonés J., Martín-Sanz P., Cascante M., Boscá L. Substrate Fate in Activated Macrophages: A Comparison between Innate, Classic, and Alternative Activation. J. Immunol. 2010;185:605–614. doi: 10.4049/jimmunol.0901698.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901698</ArticleId>
            <ArticleId IdType="pubmed">20498354</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Boroughs L.K., DeBerardinis R.J. Metabolic pathways promoting cancer cell survival and growth. Nat. Cell Biol. 2015;17:351–359. doi: 10.1038/ncb3124.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb3124</ArticleId>
            <ArticleId IdType="pmc">PMC4939711</ArticleId>
            <ArticleId IdType="pubmed">25774832</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wyss M.T., Jolivet R., Buck A., Magistretti P.J., Weber B. Evidence for Lactate as a Neuronal Energy Source. J. Neurosci. 2011;31:7477. doi: 10.1523/JNEUROSCI.0415-11.2011.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.0415-11.2011</ArticleId>
            <ArticleId IdType="pmc">PMC6622597</ArticleId>
            <ArticleId IdType="pubmed">21593331</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Díaz-García C.M., Mongeon R., Lahmann C., Koveal D., Zucker H., Yellen G. Neuronal Stimulation Triggers Neuronal Glycolysis and Not Lactate Uptake. Cell Metab. 2017;26:361–374.e4. doi: 10.1016/j.cmet.2017.06.021.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cmet.2017.06.021</ArticleId>
            <ArticleId IdType="pmc">PMC5559896</ArticleId>
            <ArticleId IdType="pubmed">28768175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bouzier-Sore A.K., Pellerin L. Unraveling the complex metabolic nature of astrocytes. Front. Cell. Neurosci. 2013;7:179. doi: 10.3389/fncel.2013.00179.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fncel.2013.00179</ArticleId>
            <ArticleId IdType="pmc">PMC3795301</ArticleId>
            <ArticleId IdType="pubmed">24130515</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Colegio O.R., Chu N.-Q., Szabo A.L., Chu T., Rhebergen A.M., Jairam V., Cyrus N., Brokowski C.E., Eisenbarth S.C., Phillips G.M., et al.  Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nat. Cell Biol. 2014;513:559–563. doi: 10.1038/nature13490.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature13490</ArticleId>
            <ArticleId IdType="pmc">PMC4301845</ArticleId>
            <ArticleId IdType="pubmed">25043024</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takenaka M.C., Gabriely G., Rothhammer V., Mascanfroni I.D., Wheeler M.A., Chao C.-C., Gutiérrez-Vázquez C., Kenison J., Tjon E.C., Barroso A., et al.  Control of tumor-associated macrophages and T cells in glioblastoma via AHR and CD39. Nat. Neurosci. 2019;22:729–740. doi: 10.1038/s41593-019-0370-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41593-019-0370-y</ArticleId>
            <ArticleId IdType="pubmed">30962630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Y., Yu G., Chu H., Wang X., Xiong L., Cai G., Liu R., Gao H., Tao B., Li W., et al.  Macrophage-Associated PGK1 Phosphorylation Promotes Aerobic Glycolysis and Tumorigenesis. Mol. Cell. 2018;71:201–215.e7. doi: 10.1016/j.molcel.2018.06.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2018.06.023</ArticleId>
            <ArticleId IdType="pubmed">30029001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Aldape K., Brindle K.M., Chesler L., Chopra R., Gajjar A., Gilbert M.R., Gottardo N., Gutmann D.H., Hargrave D., Holland E.C., et al.  Challenges to curing primary brain tumours. Nat. Rev. Clin. Oncol. 2019;16:509–520. doi: 10.1038/s41571-019-0177-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41571-019-0177-5</ArticleId>
            <ArticleId IdType="pmc">PMC6650350</ArticleId>
            <ArticleId IdType="pubmed">30733593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karachi A., Dastmalchi F., Mitchell D.A., Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro-Oncology. 2018;20:1566–1572. doi: 10.1093/neuonc/noy072.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noy072</ArticleId>
            <ArticleId IdType="pmc">PMC6231207</ArticleId>
            <ArticleId IdType="pubmed">29733389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sampson J.H., Aldape K.D., Archer G.E., Coan A., Desjardins A., Friedman A.H., Friedman H.S., Gilbert M.R., Herndon J.E., McLendon R.E., et al.  Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2010;13:324–333. doi: 10.1093/neuonc/noq157.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noq157</ArticleId>
            <ArticleId IdType="pmc">PMC3064599</ArticleId>
            <ArticleId IdType="pubmed">21149254</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batich K.A., Reap E.A., Archer G.E., Sanchez-Perez L., Nair S.K., Schmittling R.J., Norberg P., Xie W., Herndon J.E., Healy P., et al.  Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. Clin. Cancer Res. 2017;23:1898–1909. doi: 10.1158/1078-0432.CCR-16-2057.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-16-2057</ArticleId>
            <ArticleId IdType="pmc">PMC5559300</ArticleId>
            <ArticleId IdType="pubmed">28411277</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Pérez L.A., Choi B.D., Archer G.E., Cui X., Flores C., Johnson L.A., Schmittling R.J., Snyder D., Herndon J.E., Bigner D.D., et al.  Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE. 2013;8:e59082.  doi: 10.1371/journal.pone.0059082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0059082</ArticleId>
            <ArticleId IdType="pmc">PMC3601076</ArticleId>
            <ArticleId IdType="pubmed">23527092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hudson A.L., Parker N.R., Khong P., Parkinson J.F., Dwight T., Ikin R.J., Zhu Y., Chen J., Wheeler H.R., Howell V.M. Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment. Front. Oncol. 2018;8:314. doi: 10.3389/fonc.2018.00314.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2018.00314</ArticleId>
            <ArticleId IdType="pmc">PMC6099184</ArticleId>
            <ArticleId IdType="pubmed">30151353</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fadul C.E., Fisher J.L., Gui J., Hampton T.H., Côté A.L., Ernstoff M.S. Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiforme. Neuro-Oncology. 2011;13:393–400. doi: 10.1093/neuonc/noq204.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/noq204</ArticleId>
            <ArticleId IdType="pmc">PMC3064696</ArticleId>
            <ArticleId IdType="pubmed">21339188</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Genard G., Lucas S., Michiels C. Reprogramming of Tumor-Associated Macrophages with Anticancer Therapies: Radiotherapy versus Chemo- and Immunotherapies. Front. Immunol. 2017;8:828. doi: 10.3389/fimmu.2017.00828.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.00828</ArticleId>
            <ArticleId IdType="pmc">PMC5509958</ArticleId>
            <ArticleId IdType="pubmed">28769933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Seifert L., Werba G., Tiwari S., Ly N.N.G., Nguy S., Alothman S., Alqunaibit D., Avanzi A., Daley D., Barilla R., et al.  Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. Gastroenterology. 2016;150:1659–1672.e5. doi: 10.1053/j.gastro.2016.02.070.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1053/j.gastro.2016.02.070</ArticleId>
            <ArticleId IdType="pmc">PMC4909514</ArticleId>
            <ArticleId IdType="pubmed">26946344</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Majety M., Runza V., Lehmann C., Hoves S., Ries C.H. A drug development perspective on targeting tumor-associated myeloid cells. FEBS J. 2017;285:763–776. doi: 10.1111/febs.14277.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/febs.14277</ArticleId>
            <ArticleId IdType="pubmed">28941174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Coniglio S.J., Eugenin E., Dobrenis K., Stanley E.R., West B.L., Symons M.H., Segall J.E. Microglial Stimulation of Glioblastoma Invasion Involves Epidermal Growth Factor Receptor (EGFR) and Colony Stimulating Factor 1 Receptor (CSF-1R) Signaling. Mol. Med. 2012;18:519–527. doi: 10.2119/molmed.2011.00217.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2119/molmed.2011.00217</ArticleId>
            <ArticleId IdType="pmc">PMC3356419</ArticleId>
            <ArticleId IdType="pubmed">22294205</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cassetta L., Pollard J.W. Targeting macrophages: Therapeutic approaches in cancer. Nat. Rev. Drug Discov. 2018;17:887–904. doi: 10.1038/nrd.2018.169.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrd.2018.169</ArticleId>
            <ArticleId IdType="pubmed">30361552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeNardo D.G., Ruffell B. Macrophages as regulators of tumour immunity and immunotherapy. Nat. Rev. Immunol. 2019;19:369–382. doi: 10.1038/s41577-019-0127-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0127-6</ArticleId>
            <ArticleId IdType="pmc">PMC7339861</ArticleId>
            <ArticleId IdType="pubmed">30718830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pyonteck S.M., Akkari L., Schuhmacher A.J., Bowman R.L., Sevenich L., Quail D.F., Olson O.C., Quick M.L., Huse J.T., Teijeiro V., et al.  CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013;19:1264–1272. doi: 10.1038/nm.3337.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3337</ArticleId>
            <ArticleId IdType="pmc">PMC3840724</ArticleId>
            <ArticleId IdType="pubmed">24056773</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Butowski N., Colman H., De Groot J.F., Omuro A.M., Nayak L., Wen P.Y., Cloughesy T.F., Marimuthu A., Haidar S., Perry A., et al.  Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: An Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro-Oncology. 2016;18:557–564. doi: 10.1093/neuonc/nov245.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov245</ArticleId>
            <ArticleId IdType="pmc">PMC4799682</ArticleId>
            <ArticleId IdType="pubmed">26449250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>De Boeck A., Ahn B.Y., D’Mello C., Lun X., Menon S.V., AlShehri M.M., Szulzewsky F., Shen Y., Khan L., Dang N.H., et al.  Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression. Nat. Commun. 2020;11:1–24. doi: 10.1038/s41467-020-18569-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-18569-4</ArticleId>
            <ArticleId IdType="pmc">PMC7536425</ArticleId>
            <ArticleId IdType="pubmed">33020472</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ramadan A.M., Daguindau E., Rech J.C., Chinnaswamy K., Zhang J., Hura G.L., Griesenauer B., Bolten Z., Robida A., Larsen M., et al.  From proteomics to discovery of first-in-class ST2 inhibitors active in vivo. JCI Insight. 2018;3 doi: 10.1172/jci.insight.99208.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.99208</ArticleId>
            <ArticleId IdType="pmc">PMC6124397</ArticleId>
            <ArticleId IdType="pubmed">30046004</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F., Parayath N.N., Ene C.I., Stephan S.B., Koehne A.L., Coon M.E., Holland E.C., Stephan M.T. Genetic programming of macrophages to perform anti-tumor functions using targeted mRNA nanocarriers. Nat. Commun. 2019;10:1–16. doi: 10.1038/s41467-019-11911-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-11911-5</ArticleId>
            <ArticleId IdType="pmc">PMC6722139</ArticleId>
            <ArticleId IdType="pubmed">31481662</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Von Roemeling C.A., Wang Y., Qie Y., Yuan H., Zhao H., Liu X., Yang Z., Yang M., Deng W., Bruno K.A., et al.  Therapeutic modulation of phagocytosis in glioblastoma can activate both innate and adaptive antitumour immunity. Nat. Commun. 2020;11:1–12. doi: 10.1038/s41467-020-15129-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-15129-8</ArticleId>
            <ArticleId IdType="pmc">PMC7083893</ArticleId>
            <ArticleId IdType="pubmed">32198351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khasraw M., Reardon D.A., Weller M., Sampson J.H. PD-1 Inhibitors: Do they have a Future in the Treatment of Glioblastoma? Clin. Cancer Res. 2020;26:5287–5296. doi: 10.1158/1078-0432.CCR-20-1135.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1135</ArticleId>
            <ArticleId IdType="pmc">PMC7682636</ArticleId>
            <ArticleId IdType="pubmed">32527943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goswami S., Walle T., Cornish A.E., Basu S., Anandhan S., Fernandez I., Vence L., Blando J., Zhao H., Yadav S.S., et al.  Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma. Nat. Med. 2020;26:39–46. doi: 10.1038/s41591-019-0694-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0694-x</ArticleId>
            <ArticleId IdType="pmc">PMC7182038</ArticleId>
            <ArticleId IdType="pubmed">31873309</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P., Miska J., Lee-Chang C., Rashidi A., Panek W.K., An S., Zannikou M., Lopez-Rosas A., Han Y., Xiao T., et al.  Therapeutic targeting of tumor-associated myeloid cells synergizes with radiation therapy for glioblastoma. Proc. Natl. Acad. Sci. USA. 2019;116:23714–23723. doi: 10.1073/pnas.1906346116.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1906346116</ArticleId>
            <ArticleId IdType="pmc">PMC6876152</ArticleId>
            <ArticleId IdType="pubmed">31712430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F., Perego M., Gabrilovich D.I. Myeloid-derived suppressor cells coming of age. Nat. Immunol. 2018;19:108–119. doi: 10.1038/s41590-017-0022-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41590-017-0022-x</ArticleId>
            <ArticleId IdType="pmc">PMC5854158</ArticleId>
            <ArticleId IdType="pubmed">29348500</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raber P.L., Thevenot P., Sierra R., Wyczechowska D., Halle D., Ramirez M.E., Ochoa A.C., Fletcher M., Velasco C., Wilk A., et al.  Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways. Int. J. Cancer. 2014;134:2853–2864. doi: 10.1002/ijc.28622.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.28622</ArticleId>
            <ArticleId IdType="pmc">PMC3980009</ArticleId>
            <ArticleId IdType="pubmed">24259296</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Han Y., Guo Q., Zhang M., Cao X. Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 2009;182:240–249. doi: 10.4049/jimmunol.182.1.240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.182.1.240</ArticleId>
            <ArticleId IdType="pubmed">19109155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ugolini A., Tyurin V.A., Tyurina Y.Y., Tcyganov E.N., Donthireddy L., Kagan V.E., Gabrilovich D.I., Veglia F. Polymorphonuclear myeloid-derived suppressor cells limit antigen cross-presentation by dendritic cells in cancer. JCI Insight. 2020;5 doi: 10.1172/jci.insight.138581.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.138581</ArticleId>
            <ArticleId IdType="pmc">PMC7455061</ArticleId>
            <ArticleId IdType="pubmed">32584791</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang B., Pan P.-Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.-H. Gr-1+CD115+ Immature Myeloid Suppressor Cells Mediate the Development of Tumor-Induced T Regulatory Cells and T-Cell Anergy in Tumor-Bearing Host. Cancer Res. 2006;66:1123–1131. doi: 10.1158/0008-5472.CAN-05-1299.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/0008-5472.CAN-05-1299</ArticleId>
            <ArticleId IdType="pubmed">16424049</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ye Z.-P., He H.-Y., Wang H., Li W.-S., Luo L., Huang Z.-C., Guo Y. Glioma-Derived ADAM10 Induces Regulatory B Cells to Suppress CD8+ T Cells. PLoS ONE. 2014;9:e105350.  doi: 10.1371/journal.pone.0105350.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0105350</ArticleId>
            <ArticleId IdType="pmc">PMC4134303</ArticleId>
            <ArticleId IdType="pubmed">25127032</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F., Tyurin V.A., Blasi M., De Leo A., Kossenkov A.V., Donthireddy L., To T.K.J., Schug Z., Basu S., Wang F., et al.  Fatty acid transport protein 2 reprograms neutrophils in cancer. Nat. Cell Biol. 2019;569:73–78. doi: 10.1038/s41586-019-1118-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-1118-2</ArticleId>
            <ArticleId IdType="pmc">PMC6557120</ArticleId>
            <ArticleId IdType="pubmed">30996346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrilovich D.I., Ostrand-Rosenberg S., Bronte V. Coordinated regulation of myeloid cells by tumours. Nat. Rev. Immunol. 2012;12:253–268. doi: 10.1038/nri3175.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nri3175</ArticleId>
            <ArticleId IdType="pmc">PMC3587148</ArticleId>
            <ArticleId IdType="pubmed">22437938</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar V., Cheng P., Condamine T., Mony S., Languino L.R., McCaffrey J.C., Hockstein N., Guarino M., Masters G., Penman E., et al.  CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation. Immunity. 2016;44:303–315. doi: 10.1016/j.immuni.2016.01.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.01.014</ArticleId>
            <ArticleId IdType="pmc">PMC4759655</ArticleId>
            <ArticleId IdType="pubmed">26885857</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shand F.H.W., Ueha S., Otsuji M., Koid S.S., Shichino S., Tsukui T., Kosugi-Kanaya M., Abe J., Tomura M., Ziogas J., et al.  Tracking of intertissue migration reveals the origins of tumor-infiltrating monocytes. Proc. Natl. Acad. Sci. USA. 2014;111:7771–7776. doi: 10.1073/pnas.1402914111.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1402914111</ArticleId>
            <ArticleId IdType="pmc">PMC4040600</ArticleId>
            <ArticleId IdType="pubmed">24825888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Corzo C.A., Condamine T., Lu L., Cotter M.J., Youn J.-I., Cheng P., Cho H.-I., Celis E., Quiceno D.G., Padhya T., et al.  HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 2010;207:2439–2453. doi: 10.1084/jem.20100587.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20100587</ArticleId>
            <ArticleId IdType="pmc">PMC2964584</ArticleId>
            <ArticleId IdType="pubmed">20876310</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Akasaki Y., Liu G., Chung N.H.C., Ehtesham M., Black K.L., Yu J.S. Induction of a CD4+ T Regulatory Type 1 Response by Cyclooxygenase-2-Overexpressing Glioma. J. Immunol. 2004;173:4352–4359. doi: 10.4049/jimmunol.173.7.4352.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.173.7.4352</ArticleId>
            <ArticleId IdType="pubmed">15383564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raychaudhuri B., Rayman P., Ireland J., Ko J., Rini B., Borden E.C., Garcia J., Vogelbaum M.A., Finke J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro-Oncology. 2011;13:591–599. doi: 10.1093/neuonc/nor042.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nor042</ArticleId>
            <ArticleId IdType="pmc">PMC3107102</ArticleId>
            <ArticleId IdType="pubmed">21636707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dubinski D., Wölfer J., Hasselblatt M., Schneider-Hohendorf T., Bogdahn U., Stummer W., Wiendl H., Grauer O. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology. 2015;18:807–818. doi: 10.1093/neuonc/nov280.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/nov280</ArticleId>
            <ArticleId IdType="pmc">PMC4864257</ArticleId>
            <ArticleId IdType="pubmed">26578623</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gielen P.R., Schulte B.M., Kers-Rebel E.D., Verrijp K., Petersen-Baltussen H.M., Ter Laan M., Wesseling P., Adema G.J. Increase in Both CD14-Positive and CD15-Positive Myeloid-Derived Suppressor Cell Subpopulations in the Blood of Patients With Glioma But Predominance of CD15-Positive Myeloid-Derived Suppressor Cells in Glioma Tissue. J. Neuropathol. Exp. Neurol. 2015;74:390–400. doi: 10.1097/NEN.0000000000000183.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/NEN.0000000000000183</ArticleId>
            <ArticleId IdType="pubmed">25853692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gielen P.R., Schulte B.M., Kers-Rebel E.D., Verrijp K., Bossman S.A., Ter Laan M., Wesseling P., Adema G.J. Elevated levels of polymorphonuclear myeloid-derived suppressor cells in patients with glioblastoma highly express S100A8/9 and arginase and suppress T cell function. Neuro-Oncology. 2016;18:1253–1264. doi: 10.1093/neuonc/now034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/neuonc/now034</ArticleId>
            <ArticleId IdType="pmc">PMC4998996</ArticleId>
            <ArticleId IdType="pubmed">27006175</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alban T.J., Alvarado A.G., Sorensen M.D., Bayik D., Volovetz J., Serbinowski E., Mulkearns-Hubert E.E., Sinyuk M., Hale J.S., Onzi G.R., et al.  Global immune fingerprinting in glioblastoma patient peripheral blood reveals immune-suppression signatures associated with prognosis. JCI Insight. 2018;3 doi: 10.1172/jci.insight.122264.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.122264</ArticleId>
            <ArticleId IdType="pmc">PMC6238746</ArticleId>
            <ArticleId IdType="pubmed">30385717</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Umemura N., Saio M., Suwa T., Kitoh Y., Bai J., Nonaka K., Ouyang G.-F., Okada M., Balazs M., Adany R., et al.  Tumor-infiltrating myeloid-derived suppressor cells are pleiotropic-inflamed monocytes/macrophages that bear M1- and M2-type characteristics. J. Leukoc. Biol. 2008;83:1136–1144. doi: 10.1189/jlb.0907611.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0907611</ArticleId>
            <ArticleId IdType="pubmed">18285406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raychaudhuri B., Rayman P., Huang P., Grabowski M., Hambardzumyan D., Finke J.H., Vogelbaum M.A. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J. Neuro-Oncology. 2015;122:293–301. doi: 10.1007/s11060-015-1720-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-015-1720-6</ArticleId>
            <ArticleId IdType="pubmed">25579983</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bayik D., Zhou Y., Park C., Hong C., Vail D., Silver D.J., Lauko A., Roversi G., Watson D.C., Lo A., et al.  Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. Cancer Discov. 2020;10:1210–1225. doi: 10.1158/2159-8290.CD-19-1355.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-19-1355</ArticleId>
            <ArticleId IdType="pmc">PMC7415660</ArticleId>
            <ArticleId IdType="pubmed">32300059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Condamine T., Dominguez G.A., Youn J.-I., Kossenkov A.V., Mony S., Alicea-Torres K., Tcyganov E., Hashimoto A., Nefedova Y., Lin C., et al.  Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients. Sci. Immunol. 2016;1:aaf8943. doi: 10.1126/sciimmunol.aaf8943.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aaf8943</ArticleId>
            <ArticleId IdType="pmc">PMC5391495</ArticleId>
            <ArticleId IdType="pubmed">28417112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Alshetaiwi H., Pervolarakis N., McIntyre L.L., Ma D., Nguyen Q., Rath J.A., Nee K., Hernandez G., Evans K., Torosian L., et al.  Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics. Sci. Immunol. 2020;5:eaay6017. doi: 10.1126/sciimmunol.aay6017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/sciimmunol.aay6017</ArticleId>
            <ArticleId IdType="pmc">PMC7219211</ArticleId>
            <ArticleId IdType="pubmed">32086381</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mastio J., Condamine T., Dominguez G., Kossenkov A., Donthireddy L., Veglia F., Lin C., Wang F., Fu S., Zhou J., et al.  Identification of monocyte-like precursors of granulocytes in cancer as a mechanism for accumulation of PMN-MDSCs. J. Exp. Med. 2019;216:2150–2169. doi: 10.1084/jem.20181952.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20181952</ArticleId>
            <ArticleId IdType="pmc">PMC6719429</ArticleId>
            <ArticleId IdType="pubmed">31239386</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mi Y., Guo N., Luan J., Cheng J., Hu Z., Jiang P., Jin W.-L., Gao X. The Emerging Role of Myeloid-Derived Suppressor Cells in the Glioma Immune Suppressive Microenvironment. Front. Immunol. 2020;11:737. doi: 10.3389/fimmu.2020.00737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00737</ArticleId>
            <ArticleId IdType="pmc">PMC7193311</ArticleId>
            <ArticleId IdType="pubmed">32391020</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Otvos B., Silver D.J., Mulkearns-Hubert E.E., Alvarado A.G., Turaga S.M., Sorensen M.D., Rayman P., Flavahan W.A., Hale J.S., Stoltz K., et al.  Cancer Stem Cell-Secreted Macrophage Migration Inhibitory Factor Stimulates Myeloid Derived Suppressor Cell Function and Facilitates Glioblastoma Immune Evasion. Stem Cells. 2016;34:2026–2039. doi: 10.1002/stem.2393.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.2393</ArticleId>
            <ArticleId IdType="pmc">PMC5820763</ArticleId>
            <ArticleId IdType="pubmed">27145382</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Peereboom D.M., Alban T.J., Grabowski M.M., Alvarado A.G., Otvos B., Bayik D., Roversi G., McGraw M., Huang P., Mohammadi A.M., et al.  Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight. 2019;4 doi: 10.1172/jci.insight.130748.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/jci.insight.130748</ArticleId>
            <ArticleId IdType="pmc">PMC6948860</ArticleId>
            <ArticleId IdType="pubmed">31600167</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bauer M., Goldstein M., Heylmann D., Kaina B. Human monocytes undergo excessive apoptosis following temozolomide activating the ATM/ATR pathway while dendritic cells and macrophages are resistant. PLoS ONE. 2012;7:e39956.  doi: 10.1371/journal.pone.0039956.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0039956</ArticleId>
            <ArticleId IdType="pmc">PMC3386965</ArticleId>
            <ArticleId IdType="pubmed">22768182</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ostrand-Rosenberg S., Horn L.A., Ciavattone N.G. Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy. Front. Oncol. 2019;9:215. doi: 10.3389/fonc.2019.00215.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fonc.2019.00215</ArticleId>
            <ArticleId IdType="pmc">PMC6454107</ArticleId>
            <ArticleId IdType="pubmed">31001479</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Noman M.Z., DeSantis G., Janji B., Hasmim M., Karray S., Dessen P., Bronte V., Chouaib S. PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J. Exp. Med. 2014;211:781–790. doi: 10.1084/jem.20131916.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20131916</ArticleId>
            <ArticleId IdType="pmc">PMC4010891</ArticleId>
            <ArticleId IdType="pubmed">24778419</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan J., Li R., Yin L.-M., Deng L., Gui J., Chen B.-Q., Zhou L., Meng M.-B., Huang Q.-R., Mo X.-M., et al.  Targeting Myeloid-derived Suppressor Cells and Programmed Death Ligand 1 Confers Therapeutic Advantage of Ablative Hypofractionated Radiation Therapy Compared With Conventional Fractionated Radiation Therapy. Int. J. Radiat. Oncol. 2018;101:74–87. doi: 10.1016/j.ijrobp.2018.01.071.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijrobp.2018.01.071</ArticleId>
            <ArticleId IdType="pubmed">29619980</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhu X., Fujita M., Snyder L.A., Okada H. Systemic delivery of neutralizing antibody targeting CCL2 for glioma therapy. J. Neurooncol. 2011;104:83–92. doi: 10.1007/s11060-010-0473-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-010-0473-5</ArticleId>
            <ArticleId IdType="pmc">PMC3068234</ArticleId>
            <ArticleId IdType="pubmed">21116835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gabrusiewicz K., Colwell N.A., Heimberger A.B.  In: Translational Immunotherapy of Brain Tumors. Sampson J.H., editor. Academic Press; Cambridge, MA, USA: 2017. pp. 63–82.</Citation>
        </Reference>
        <Reference>
          <Citation>Alban T.J., Bayik D., Otvos B., Rabljenovic A., Leng L., Jia-Shiun L., Roversi G., Lauko A., Momin A.A., Mohammadi A.M., et al.  Glioblastoma Myeloid-Derived Suppressor Cell Subsets Express Differential Macrophage Migration Inhibitory Factor Receptor Profiles That Can Be Targeted to Reduce Immune Suppression. Front. Immunol. 2020;11:1191. doi: 10.3389/fimmu.2020.01191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.01191</ArticleId>
            <ArticleId IdType="pmc">PMC7315581</ArticleId>
            <ArticleId IdType="pubmed">32625208</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu C., Muroski M.E., Miska J., Lee-Chang C., Shen Y., Rashidi A., Zhang P., Xiao T., Han Y., Lopez-Rosas A., et al.  Repolarization of myeloid derived suppressor cells via magnetic nanoparticles to promote radiotherapy for glioma treatment. Nanomed.: Nanotechnol. Biol. Med. 2019;16:126–137. doi: 10.1016/j.nano.2018.11.015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.nano.2018.11.015</ArticleId>
            <ArticleId IdType="pubmed">30553919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pelletier M., Maggi L., Micheletti A., Lazzeri E., Tamassia N., Costantini C., Cosmi L., Lunardi C., Annunziato F., Romagnani S., et al.  Evidence for a cross-talk between human neutrophils and Th17 cells. Blood. 2010;115:335–343. doi: 10.1182/blood-2009-04-216085.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2009-04-216085</ArticleId>
            <ArticleId IdType="pubmed">19890092</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Massara M., Persico P., Bonavita O., Poeta V.M., Locati M., Simonelli M., Bonecchi R. Neutrophils in Gliomas. Front. Immunol. 2017;8:1349. doi: 10.3389/fimmu.2017.01349.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2017.01349</ArticleId>
            <ArticleId IdType="pmc">PMC5662581</ArticleId>
            <ArticleId IdType="pubmed">29123517</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zadora P., Dabrowski W., Czarko K., Smolen A., Kotlinska-Hasiec E., Wiorkowski K., Sikora A., Jarosz B., Kura K., Rola R., et al.  Preoperative neutrophil–Lymphocyte count ratio helps predict the grade of glial tumor–A pilot study. Neurol. Neurochir. Polska. 2015;49:41–44. doi: 10.1016/j.pjnns.2014.12.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.pjnns.2014.12.006</ArticleId>
            <ArticleId IdType="pubmed">25666772</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bambury R.M., Teo M.Y., Power D.G., Yusuf A., Murray S., Battley J.E., Drake C., O’Dea P., Bermingham N., Keohane C., et al.  The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme. J. Neuro-Oncol. 2013;114:149–154. doi: 10.1007/s11060-013-1164-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-013-1164-9</ArticleId>
            <ArticleId IdType="pubmed">23780645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mason M., Maurice C., McNamara M.G., Tieu M.T., Lwin Z., Millar B.-A., Menard C., Laperriere N., Milosevic M., Atenafu E.G., et al.  Neutrophil–lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival. J. Neuro-Oncol. 2017;132:463–471. doi: 10.1007/s11060-017-2395-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11060-017-2395-y</ArticleId>
            <ArticleId IdType="pubmed">28332000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schernberg A., Nivet A., Dhermain F., Ammari S., Escande A., Pallud J., Louvel G., Deutsch E. Neutrophilia as a biomarker for overall survival in newly diagnosed high-grade glioma patients undergoing chemoradiation. Clin. Transl. Radiat. Oncol. 2018;10:47–52. doi: 10.1016/j.ctro.2018.04.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ctro.2018.04.002</ArticleId>
            <ArticleId IdType="pmc">PMC6008628</ArticleId>
            <ArticleId IdType="pubmed">29928705</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rahbar A., Cederarv M., Wolmer-Solberg N., Tammik C., Stragliotto G., Peredo I., Fornara O., Xu X., Dzabic M., Taher C., et al.  Enhanced neutrophil activity is associated with shorter time to tumor progression in glioblastoma patients. OncoImmunology. 2015;5:e1075693. doi: 10.1080/2162402X.2015.1075693.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/2162402X.2015.1075693</ArticleId>
            <ArticleId IdType="pmc">PMC4801436</ArticleId>
            <ArticleId IdType="pubmed">27057448</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hor W.S., Huang W.L., Lin Y.S., Yang B.C. Cross-talk between tumor cells and neutrophils through the Fas (APO-1, CD95)/FasL system: Human glioma cells enhance cell viability and stimulate cytokine production in neutrophils. J. Leukoc. Biol. 2003;73:363–368. doi: 10.1189/jlb.0702375.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1189/jlb.0702375</ArticleId>
            <ArticleId IdType="pubmed">12629150</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chio C.C., Wang Y.S., Chen Y.L., Lin S.J., Yang B.C. Down-regulation of Fas-L in glioma cells by ribozyme reduces cell apoptosis, tumour-infiltrating cells, and liver damage but accelerates tumour formation in nude mice. Br. J. Cancer. 2001;85:1185–1192. doi: 10.1054/bjoc.2001.2055.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1054/bjoc.2001.2055</ArticleId>
            <ArticleId IdType="pmc">PMC2375147</ArticleId>
            <ArticleId IdType="pubmed">11710833</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iwatsuki K.-C., Kumara E., Yoshimine T.-C., Nakagawa H.-C., Sato M., Hayakawa T. Elastase expression by infiltrating neutrophils in gliomas. Neurol. Res. 2000;22:465–468. doi: 10.1080/01616412.2000.11740701.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/01616412.2000.11740701</ArticleId>
            <ArticleId IdType="pubmed">10935217</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liang J., Piao Y., Holmes L., Fuller G.N., Henry V., Tiao N., De Groot J.F. Neutrophils Promote the Malignant Glioma Phenotype through S100A4. Clin. Cancer Res. 2014;20:187–198. doi: 10.1158/1078-0432.CCR-13-1279.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-13-1279</ArticleId>
            <ArticleId IdType="pmc">PMC4422653</ArticleId>
            <ArticleId IdType="pubmed">24240114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manda-Handzlik A., Demkow U. The Brain Entangled: The Contribution of Neutrophil Extracellular Traps to the Diseases of the Central Nervous System. Cells. 2019;8:1477.  doi: 10.3390/cells8121477.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cells8121477</ArticleId>
            <ArticleId IdType="pmc">PMC6953104</ArticleId>
            <ArticleId IdType="pubmed">31766346</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sippel T.R., White J., Nag K., Tsvankin V., Klaassen M., Kleinschmidt-DeMasters B.K., Waziri A. Neutrophil Degranulation and Immunosuppression in Patients with GBM: Restoration of Cellular Immune Function by Targeting Arginase I. Clin. Cancer Res. 2011;17:6992–7002. doi: 10.1158/1078-0432.CCR-11-1107.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-11-1107</ArticleId>
            <ArticleId IdType="pubmed">21948231</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yee P.P., Wei Y., Kim S.-Y., Lu T., Chih S.Y., Lawson C., Tang M., Liu Z., Anderson B., Thamburaj K., et al.  Neutrophil-induced ferroptosis promotes tumor necrosis in glioblastoma progression. Nat. Commun. 2020;11:1–22. doi: 10.1038/s41467-020-19193-y.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-19193-y</ArticleId>
            <ArticleId IdType="pmc">PMC7591536</ArticleId>
            <ArticleId IdType="pubmed">33110073</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zilionis R., Engblom C., Pfirschke C., Savova V., Zemmour D., Saatcioglu H.D., Krishnan I., Maroni G., Meyerovitz C.V., Kerwin C.M., et al.  Single-Cell Transcriptomics of Human and Mouse Lung Cancers Reveals Conserved Myeloid Populations across Individuals and Species. Immunity. 2019;50:1317–1334.e10. doi: 10.1016/j.immuni.2019.03.009.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2019.03.009</ArticleId>
            <ArticleId IdType="pmc">PMC6620049</ArticleId>
            <ArticleId IdType="pubmed">30979687</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ng L.G., Ostuni R., Hidalgo A. Heterogeneity of neutrophils. Nat. Rev. Immunol. 2019;19:255–265. doi: 10.1038/s41577-019-0141-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0141-8</ArticleId>
            <ArticleId IdType="pubmed">30816340</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sagiv J.Y., Michaeli J., Assi S., Mishalian I., Kisos H., Levy L., Damti P., Lumbroso D., Polyansky L., Sionov R.V., et al.  Phenotypic Diversity and Plasticity in Circulating Neutrophil Subpopulations in Cancer. Cell Rep. 2015;10:562–573. doi: 10.1016/j.celrep.2014.12.039.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.12.039</ArticleId>
            <ArticleId IdType="pubmed">25620698</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mishalian I., Bayuh R., Levy L., Zolotarov L., Michaeli J., Fridlender Z.G. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. Cancer Immunol. Immunother. 2013;62:1745–1756. doi: 10.1007/s00262-013-1476-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00262-013-1476-9</ArticleId>
            <ArticleId IdType="pubmed">24092389</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Strauss L., Sangaletti S., Consonni F.M., Szebeni G., Morlacchi S., Totaro M.G., Porta C., Anselmo A., Tartari S., Doni A., et al.  RORC1 Regulates Tumor-Promoting “Emergency” Granulo-Monocytopoiesis. Cancer Cell. 2015;28:253–269. doi: 10.1016/j.ccell.2015.07.006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2015.07.006</ArticleId>
            <ArticleId IdType="pubmed">26267538</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chai E., Zhang L., Li C. LOX-1+ PMN-MDSC enhances immune suppression which promotes glioblastoma multiforme progression. Cancer Manag. Res. 2019;11:7307–7315. doi: 10.2147/CMAR.S210545.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2147/CMAR.S210545</ArticleId>
            <ArticleId IdType="pmc">PMC6683959</ArticleId>
            <ArticleId IdType="pubmed">31447588</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F., Gabrilovich D.I. Dendritic cells in cancer: The role revisited. Curr. Opin. Immunol. 2017;45:43–51. doi: 10.1016/j.coi.2017.01.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.coi.2017.01.002</ArticleId>
            <ArticleId IdType="pmc">PMC5449252</ArticleId>
            <ArticleId IdType="pubmed">28192720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fogg D.K., Sibon C., Miled C., Jung S., Aucouturier P., Littman D.R., Cumano A., Geissmann F. A Clonogenic Bone Marrow Progenitor Specific for Macrophages and Dendritic Cells. Science. 2006;311:83–87. doi: 10.1126/science.1117729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.1117729</ArticleId>
            <ArticleId IdType="pubmed">16322423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Merad M., Sathe P., Helft J., Miller J., Mortha A. The Dendritic Cell Lineage: Ontogeny and Function of Dendritic Cells and Their Subsets in the Steady State and the Inflamed Setting. Annu. Rev. Immunol. 2013;31:563–604. doi: 10.1146/annurev-immunol-020711-074950.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1146/annurev-immunol-020711-074950</ArticleId>
            <ArticleId IdType="pmc">PMC3853342</ArticleId>
            <ArticleId IdType="pubmed">23516985</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Segura E., Amigorena S. Identification of human inflammatory dendritic cells. Oncoimmunology. 2013;2:e23851. doi: 10.4161/onci.23851.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4161/onci.23851</ArticleId>
            <ArticleId IdType="pmc">PMC3667892</ArticleId>
            <ArticleId IdType="pubmed">23762786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>D’Agostino P.M., Gottfried-Blackmore A., Anandasabapathy N., Bulloch K. Brain dendritic cells: Biology and pathology. Acta Neuropathol. 2012;124:599–614. doi: 10.1007/s00401-012-1018-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-012-1018-0</ArticleId>
            <ArticleId IdType="pmc">PMC3700359</ArticleId>
            <ArticleId IdType="pubmed">22825593</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Veglia F., Tyurin V.A., Mohammadyani D., Blasi M., Duperret E.K., Donthireddy L., Hashimoto A., Kapralov A., Amoscato A., Angelini R., et al.  Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. Nat. Commun. 2017;8:1–16. doi: 10.1038/s41467-017-02186-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-017-02186-9</ArticleId>
            <ArticleId IdType="pmc">PMC5730553</ArticleId>
            <ArticleId IdType="pubmed">29242535</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broz M.L., Binnewies M., Boldajipour B., Nelson A.E., Pollack J.L., Erle D.J., Barczak A., Rosenblum M.D., Daud A., Barber D.L., et al.  Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell Immunity. Cancer Cell. 2014;26:638–652. doi: 10.1016/j.ccell.2014.09.007.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2014.09.007</ArticleId>
            <ArticleId IdType="pmc">PMC4254577</ArticleId>
            <ArticleId IdType="pubmed">25446897</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Salmon H., Idoyaga J., Rahman A., Leboeuf M., Remark R., Jordan S., Casanova-Acebes M., Khudoynazarova M., Agudo J., Tung N., et al.  Expansion and Activation of CD103 + Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016;44:924–938. doi: 10.1016/j.immuni.2016.03.012.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.immuni.2016.03.012</ArticleId>
            <ArticleId IdType="pmc">PMC4980762</ArticleId>
            <ArticleId IdType="pubmed">27096321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sánchez-Paulete A.R., Cueto F.J., Martínez-López M., Labiano S., Morales-Kastresana A., Rodríguez-Ruiz M.E., Jure-Kunkel M., Azpilikueta A., Aznar M.A., Quetglas J.I., et al.  Cancer Immunotherapy with Immunomodulatory Anti-CD137 and Anti-PD-1 Monoclonal Antibodies Requires BATF3-Dependent Dendritic Cells. Cancer Discov. 2016;6:71–79. doi: 10.1158/2159-8290.CD-15-0510.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/2159-8290.CD-15-0510</ArticleId>
            <ArticleId IdType="pmc">PMC5036540</ArticleId>
            <ArticleId IdType="pubmed">26493961</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Spranger S., Dai D., Horton B., Gajewski T.F. Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell Therapy. Cancer Cell. 2017;31:711–723.e714. doi: 10.1016/j.ccell.2017.04.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccell.2017.04.003</ArticleId>
            <ArticleId IdType="pmc">PMC5650691</ArticleId>
            <ArticleId IdType="pubmed">28486109</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jain P., Coisne C., Enzmann G., Rottapel R., Engelhardt B. Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis. J. Immunol. 2010;184:7196–7206. doi: 10.4049/jimmunol.0901404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4049/jimmunol.0901404</ArticleId>
            <ArticleId IdType="pmc">PMC3999618</ArticleId>
            <ArticleId IdType="pubmed">20483748</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miller S.D., McMahon E.J., Schreiner B., Bailey S.L. Antigen presentation in the CNS by myeloid dendritic cells drives progression of relapsing experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 2007;1103:179–191. doi: 10.1196/annals.1394.023.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1196/annals.1394.023</ArticleId>
            <ArticleId IdType="pubmed">17376826</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wculek S.K., Cueto F.J., Mujal A.M., Melero I., Krummel M., Sancho D. Dendritic cells in cancer immunology and immunotherapy. Nat. Rev. Immunol. 2020;20:7–24. doi: 10.1038/s41577-019-0210-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41577-019-0210-z</ArticleId>
            <ArticleId IdType="pubmed">31467405</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yan J., Zhao Q., Gabrusiewicz K., Kong L.-Y., Xia X., Wang J., Ott M., Xu J., Davis R.E., Huo L., et al.  Author Correction: FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation. Nat. Commun. 2019;10:1. doi: 10.1038/s41467-019-08770-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-019-08770-5</ArticleId>
            <ArticleId IdType="pmc">PMC6377651</ArticleId>
            <ArticleId IdType="pubmed">30770835</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang J., Liu P., Xin S., Wang Z., Li J. Nrf2 suppresses the function of dendritic cells to facilitate the immune escape of glioma cells. Exp. Cell Res. 2017;360:66–73. doi: 10.1016/j.yexcr.2017.07.031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.yexcr.2017.07.031</ArticleId>
            <ArticleId IdType="pubmed">28782555</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Srivastava S., Jackson C., Kim T., Choi J., Lim M. A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials. Cancers. 2019;11:537.  doi: 10.3390/cancers11040537.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers11040537</ArticleId>
            <ArticleId IdType="pmc">PMC6521200</ArticleId>
            <ArticleId IdType="pubmed">30991681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mitchell D.A., Batich K.A., Gunn M.D., Huang M.-N., Sanchez-Perez L., Nair S.K., Congdon K.L., Reap E.A., Archer G.E., Desjardins A., et al.  Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nat. Cell Biol. 2015;519:366–369. doi: 10.1038/nature14320.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14320</ArticleId>
            <ArticleId IdType="pmc">PMC4510871</ArticleId>
            <ArticleId IdType="pubmed">25762141</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Batich K.A., Mitchell D.A., Healy P., Herndon J.E., Sampson J.H., 2nd Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. Clin. Cancer Res. 2020;26:5297–5303. doi: 10.1158/1078-0432.CCR-20-1082.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-20-1082</ArticleId>
            <ArticleId IdType="pubmed">32719000</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei H., Wang S., Zhang D., Hou S., Qian W., Li B., Guo H., Kou G., He J., Wang H., et al.  Targeted Delivery of Tumor Antigens to Activated Dendritic Cells via CD11c Molecules Induces Potent Antitumor Immunity in Mice. Clin. Cancer Res. 2009;15:4612–4621. doi: 10.1158/1078-0432.CCR-08-3321.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-08-3321</ArticleId>
            <ArticleId IdType="pubmed">19584156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bonifaz L.C., Bonnyay D.P., Charalambous A., Darguste D.I., Fujii S.-I., Soares H., Brimnes M.K., Moltedo B., Moran T.M., Steinman R.M. In Vivo Targeting of Antigens to Maturing Dendritic Cells via the DEC-205 Receptor Improves T Cell Vaccination. J. Exp. Med. 2004;199:815–824. doi: 10.1084/jem.20032220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1084/jem.20032220</ArticleId>
            <ArticleId IdType="pmc">PMC2212731</ArticleId>
            <ArticleId IdType="pubmed">15024047</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garzon-Muvdi T., Theodros D., Luksik A.S., Maxwell R., Kim E., Jackson C.M., Belcaid Z., Ganguly S., Tyler B., Brem H., et al.  Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma. Oncotarget. 2018;9:20681–20697. doi: 10.18632/oncotarget.25061.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.25061</ArticleId>
            <ArticleId IdType="pmc">PMC5945499</ArticleId>
            <ArticleId IdType="pubmed">29755681</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Miao X., Chen Y., Hao K., Zheng M., Chen B., Li K., Wang Y., Zhang W., Zhang Y., Mou X., et al.  CD103+ Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model. Oncol. Res. Featur. Preclin. Clin. Cancer Ther. 2018;26:173–182. doi: 10.3727/096504017X14841698396865.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3727/096504017X14841698396865</ArticleId>
            <ArticleId IdType="pmc">PMC7844614</ArticleId>
            <ArticleId IdType="pubmed">28109087</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hammerich L., Marron T.U., Upadhyay R., Svensson-Arvelund J., Dhainaut M., Hussein S., Zhan Y., Ostrowski D., Yellin M., Marsh H.C., et al.  Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat. Med. 2019;25:814–824. doi: 10.1038/s41591-019-0410-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41591-019-0410-x</ArticleId>
            <ArticleId IdType="pubmed">30962585</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Flores C.T., Wildes T.J., Drake J.A., Moore G.L., Dean B.D., Abraham R.S., Mitchell D.A. Lin−CCR2+ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. Nat. Commun. 2018;9:1–14. doi: 10.1038/s41467-018-06182-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-018-06182-5</ArticleId>
            <ArticleId IdType="pmc">PMC6192988</ArticleId>
            <ArticleId IdType="pubmed">30333482</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
